IL13 and Increased total eosinophil count: For example, blood eosinophilia has been shown as a targeted biomarker linked to corticosteroids, as well as anti-IL-4-, anti-IL-13-, and anti-IL-5-targeted treatment; sputum eosinophil levels are also used as biomarkers for predicting treatment responses to inhaled steroids and anti-IL-13 and anti-IL-5 treatment; whilst serum periostin levels are linked to anti-IL-13 therapy, periostin present in bronchial tissue has been shown as a biomarker for eosinophilic airway inflammation [40].